|
1
|
Rosnet O, Matteï MG, Marchetto S and
Birnbaum D: Isolation and chromosomal localization of a novel
FMS-like tyrosine kinase gene. Genomics. 9:380–385. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa
S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y and Naoe T:
Internal tandem duplication of the FLT3 gene is preferentially seen
in acute myeloid leukemia and myelodysplastic syndrome among
various hematological malignancies. A study on a large series of
patients and cell lines. Leukemia. 11:1605–1609. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gilliland DG and Griffin JD: The roles of
FLT3 in hematopoiesis and leukemia. Blood. 100:1532–1542. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi S: Downstream molecular pathways
of FLT3 in the pathogenesis of acute myeloid leukemia: Biology and
therapeutic implications. J Hematol Oncol. 4:132011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozeki K, Kiyoi H, Hirose Y, Iwai M,
Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama
H, et al: Biologic and clinical significance of the FLT3 transcript
level in acute myeloid leukemia. Blood. 103:1901–1908. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takahashi S, Harigae H, Ishii KK, Inomata
M, Fujiwara T, Yokoyama H, Ishizawa K, Kameoka J, Licht JD, Sasaki
T and Kaku M: Over-expression of Flt3 induces NF-kappaB pathway and
increases the expression of IL-6. Leuk Res. 29:893–899. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takahashi S, Harigae H, Kaku M, Sasaki T
and Licht JD: Flt3 mutation activates p21 (WAF1/CIP1) gene
expression through the action of STAT5. Biochem Biophys Res Commun.
316:85–92. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi S, McConnell MJ, Harigae H, Kaku
M, Sasaki T, Melnick AM and Licht JD: The Flt3 internal tandem
duplication mutant inhibits the function of transcriptional
repressors by blocking interactions with SMRT. Blood.
103:4650–4658. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kiyoi H, Ohno R, Ueda R, Saito H and Naoe
T: Mechanism of constitutive activation of FLT3 with internal
tandem duplication in the juxtamembrane domain. Oncogene.
21:2555–2563. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R,
Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C,
et al: Activating mutation of D835 within the activation loop of
FLT3 in human hematologic malignancies. Blood. 97:2434–2439. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kottaridis PD, Gale RE, Frew ME, Harrison
G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett
AK, et al: The presence of a FLT3 internal tandem duplication in
patients with acute myeloid leukemia (AML) adds important
prognostic information to cytogenetic risk group and response to
the first cycle of chemotherapy: Analysis of 854 patients from the
United Kingdom medical research council AML 10 and 12 trials.
Blood. 98:1752–1759. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meshinchi S, Woods WG, Stirewalt DL,
Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID and Radich JP:
Prevalence and prognostic significance of Flt3 internal tandem
duplication in pediatric acute myeloid leukemia. Blood. 97:89–94.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kiyoi H, Naoe T, Nakano Y, Yokota S,
Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, et
al: Prognostic implication of FLT3 and N-RAS gene mutations in
acute myeloid leukemia. Blood. 93:3074–3080. 1999.PubMed/NCBI
|
|
14
|
Frohling S, Schlenk RF, Breitruck J,
Benner A, Kreitmeier S, Tobis K, Döhner H and Döhner K: AML Study
Group Ulm. Acute myeloid leukemia: Prognostic significance of
activating FLT3 mutations in younger adults (16 to 60 years) with
acute myeloid leukemia and normal cytogenetics: A study of the AML
Study Group Ulm. Blood. 100:4372–4380. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiede C, Steudel C, Mohr B, Schaich M,
Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M,
Neubauer A, et al: Analysis of FLT3-activating mutations in 979
patients with acute myelogenous leukemia: Association with FAB
subtypes and identification of subgroups with poor prognosis.
Blood. 99:4326–4335. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pardee TS, Zuber J and Lowe SW: Flt3-ITD
alters chemotherapy response in vitro and in vivo in a
p53-dependent manner. Exp Hematol. 39:473.e4–485.e4. 2011.
View Article : Google Scholar
|
|
17
|
Seedhouse CH, Hunter HM, Lloyd-Lewis B,
Massip AM, Pallis M, Carter GI, Grundy M, Shang S and Russell NH:
DNA repair contributes to the drug-resistant phenotype of primary
acute myeloid leukaemia cells with FLT3 internal tandem
duplications and is reversed by the FLT3 inhibitor PKC412.
Leukemia. 20:2130–2136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zwaan CM, Meshinchi S, Radich JP, Veerman
AJ, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R,
Zimmermann M, et al: FLT3 internal tandem duplication in 234
children with acute myeloid leukemia: Prognostic significance and
relation to cellular drug resistance. Blood. 102:2387–2394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin G, Matsushita H, Asai S, Tsukamoto H,
Ono R, Nosaka T, Yahata T, Takahashi S and Miyachi H: FLT3-ITD
induces ara-C resistance in myeloid leukemic cells through the
repression of the ENT1 expression. Biochem Biophys Res Commun.
390:1001–1006. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spiekermann K, Bagrintseva K, Schwab R,
Schmieja K and Hiddemann W: Overexpression and constitutive
activation of FLT3 induces STAT5 activation in primary acute
myeloid leukemia blast cells. Clin Cancer Res. 9:2140–2150.
2003.PubMed/NCBI
|
|
21
|
Takahashi S, Harigae H, Kameoka J, Sasaki
T and Kaku M: AML1B transcriptional repressor function is impaired
by the Flt3 internal tandem duplication. Br J Haematol.
130:428–436. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iseki Y, Nakahara M, Kubo M, Obata F,
Harigae H and Takahashi S: Correlation of PU.1 and signal
regulatory protein α1 expression in PU.1 transgenic K562 cells. Int
J Mol Med. 29:319–323. 2012.PubMed/NCBI
|
|
23
|
Hayakawa F, Towatari M, Kiyoi H, Tanimoto
M, Kitamura T, Saito H and Naoe T: Tandem-duplicated Flt3
constitutively activates STAT5 and MAP kinase and introduces
autonomous cell growth in IL-3-dependent cell lines. Oncogene.
19:624–631. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fernandez HF, Sun Z, Yao X, Litzow MR,
Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP,
Bennett JM, et al: Anthracycline dose intensification in acute
myeloid leukemia. N Engl J Med. 361:1249–1259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee BD, Sevcikova S and Kogan SC: Dual
treatment with FLT3 inhibitor SU11657 and doxorubicin increases
survival of leukemic mice. Leuk Res. 31:1131–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Janicke RU, Sohn D and Schulze-Osthoff K:
The dark side of a tumor suppressor: Anti-apoptotic p53. Cell Death
Differ. 15:959–976. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sallmyr A, Fan J, Datta K, Kim KT, Grosu
D, Shapiro P, Small D and Rassool F: Internal tandem duplication of
FLT3 (FLT3/ITD) induces increased ROS production, DNA damage and
misrepair: Implications for poor prognosis in AML. Blood.
111:3173–3182. 2008. View Article : Google Scholar : PubMed/NCBI
|
